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1. Introduction  
Gestational diabetes (GD) is defined as carbohydrate intolerance that begins or is first 
diagnosed during pregnancy. Hyperglycemia is found only during pregnancy and 
diagnosis is confirmed when glucose tolerance test results return to normal levels in the 
postpartum (Metzger et al., 2007). GD occurs in around 4-10% of pregnancies; however, its 
incidence varies as a function of nutritional habits and differences in genetic patterns 
between populations (Metzger et al., 2007). 
The importance of GD was first described around forty years ago when it was noticed that 
women with this disorder were more likely to develop diabetes mellitus later on in their 
lives. The original diagnostic criteria proposed by O’Sullivan and Mahan were in fact never 
validated for the development of gestational complications or adverse perinatal outcomes 
(O’Sullivan and Mahan, 1964). Throughout all this time, the importance of this diagnosis for 
the prognosis of the pregnancy has been the subject of debate (Holt et al., 2011). Whereas 
some specialists feared that even mild levels of hyperglycemia would negatively affect 
pregnancy outcome, others have questioned the very existence of GD as a disease 
(Buchanan and Kjos, 1999). 
Recently, however, the harmful effects of hyperglycemia during pregnancy have been 
demonstrated (HAPO, 2008) and evidence is mounting on the risks of hyperglycemia during 
pregnancy, not only in terms of adverse perinatal outcome, but also for the future of the infant 
in adult life (Catalano, 2010; Chandler-Laney et al., 2011; Fall, 2010; Lawlor et al., 2011). 
In this chapter, the rationale and current recommendations for the diagnosis and treatment of 
gestational diabetes will be evaluated based on the best scientific evidence currently available. 
The MEDLINE, EMBASE, SCOPUS and SciELO databases and the systematic reviews of the 
Cochrane Library were reassessed using the key words: gestational diabetes, screening, 
diagnosis and therapy. Preference was given to randomized clinical trials and meta-analyses, 
with observational studies and review articles being included only when studies with a better 
level of evidence were unavailable. Guidelines and recommendations established by medical 
societies for the screening, diagnosis and treatment of gestational diabetes were also consulted. 
2. Physiopathology 
As any carbohydrate metabolism disorder, GD is characterized by insufficient insulin levels 
for insulin demand (Metzger et al., 2007). The cause of this insulin insufficiency in 
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pregnancy remains to be fully established; however, it is believed that the occurrence of this 
event during pregnancy reveals underlying maternal pancreatic disorders that would 
otherwise only become apparent later on in the woman’s life (Metzger et al., 2007). 
In a normal pregnancy, fetal and placental growth increases cortisol, growth hormone, 
human placental lactogen, progesterone, estrogen and prolactin levels. The presence of these 
stimuli triggers hyperinsulinemia, insulin resistance, fasting hypoglycemia and postprandial 
hyperglycemia. Consequently, there is a reduction in peripheral sensitivity to insulin and an 
increase in demand. As a compensatory mechanism, an increase occurs in pancreatic 
function at the cost of both hypertrophy and hyperplasia. Furthermore, in response to the 
high insulin levels, peripheral utilization of glucose by the muscles and peripheral glycogen 
storage increase in an attempt to maintain balance (Metzger et al., 2007; Pridjian and 
Benjamin, 2010). 
As pregnancy advances, these compensatory mechanisms may be insufficient in susceptible 
women, resulting in an imbalance between insulin production and insulin requirements in 
pregnancy. Compared to a normal pregnant woman, a woman with GD has pancreatic β-
cell dysfunction and a reduction in adaptive β-cell capacity. This results in insufficient 
insulin secretion and consequent hyperglycemia (Metzger et al., 2007; Pridjian and 
Benjamin, 2010). 
3. Consequences for the mother and child   
The consequences of gestational diabetes for the mother and child are summarized in Table 1. 
 
Risks of Gestational Diabetes 
Mother Fetus Newborn infant Child/Adult 
Obstetric 
trauma 
Hyperinsulinemia: 
• Large for gestational age 
• Macrosomia 
Respiratory distress 
syndrome 
Obesity 
Higher rate of 
Cesarean 
sections 
Cardiomyopathy Hypoglycemia Type 2 Diabetes 
Mellitus  
Preeclampsia/ 
gestational 
hypertension 
Obstetric trauma: 
• Shoulder dystocia  
• Fractures 
• Brachial plexus lesion 
Hypocalcemia Metabolic 
syndrome 
Type 2 Diabetes 
mellitus 
Stillbirth Hypomagnesemia  
Metabolic 
syndrome 
 Polycythemia: 
• Hyperviscosity 
• Hyperbilirubinemia 
Cardiomyopathy 
 
Modified from Pridjian and Benjamin, 2010  
Table 1. Risks of Gestational Diabetes 
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4. Screening and diagnosis of gestational diabetes 
The screening and diagnosis of GD is the subject of intense debate and controversy 
worldwide (Holt et al., 2011; Leary et al., 2010). All aspects of diagnosis (who should be 
investigated, using which tests and what values are considered diagnostic) have been 
widely discussed over the past two decades (Holt et al., 2011). Consequently, the guidelines 
published by the major societies differ with respect to these aspects with the result that the 
practices of physicians worldwide differ to the same extent (Leary et al., 2010). 
The World Health Organization (WHO) recommends screening high-risk women with a 75-
gram oral glucose tolerance test in the first trimester of pregnancy and all other women at 
24-28 weeks, with fasting glucose measurements of 126 mg/dl and two-hour glucose levels 
of 140 mg/dl being considered abnormal (WHO, 1999). However, until recently (up to 
autumn 2010), the American Diabetes Association (ADA) recommended screening only 
women with risk factors and advocated an oral load of 100 grams of anhydrous glucose 
(ADA, 2004). The values adopted in each one of the guidelines also differed greatly. 
Recently, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) 
assembled the evidence accumulated over recent years and published new criteria for the 
screening and diagnosis of GD (IADPSG, Metzger et al., 2010). 
4.1 Screening 
Screening is performed to select individuals to be investigated. Since 1999, the World Health 
Organization (WHO) has recommended the screening of all women or all women except 
those considered low-risk (WHO, 1999). 
In 2003, a US taskforce was formed to evaluate screening for gestational diabetes. The 
authors’ conclusion was that better-quality evidence was required to determine whether the 
benefits of screening are greater than the risks. They recommended that until such evidence 
was available, to screen or not to screen should be left to the discretion of each individual 
physician according to his/her own clinical judgment and that both options are reasonable 
(The US Preventive Services Task-Force – USPSTF, Brody et al., 2003-A). 
The same taskforce evaluated the risk factors for gestational diabetes and found a strong 
association with: maternal obesity (body mass index > 25), age > 25 years, personal or family 
history of a carbohydrate metabolism disorder or a history of gestational diabetes in a 
previous pregnancy. Some ethnic groups such as Hispanics, Blacks, native American 
Indians and Asians are also at an increased risk of developing gestational diabetes. If all 
these criteria are taken into consideration, 90% of all women at risk of developing 
gestational diabetes will be identified (Brody et al., 2003-A). 
A systematic review was conducted of observational studies published in the past thirty 
years to evaluate the presence and strength of the association between pre-gestational body 
mass index (BMI) and the presence of gestational diabetes. Seventy studies were included 
involving 671,945 women (59 cohort studies and 11 case-control studies). Compared to 
women with normal pregestational BMI, in accordance with the odds ratio (OR) the 
estimated risk of developing gestational diabetes was 1.97 [95% confidence interval (95%CI) 
1.77 – 2.19], 3.01 [95%CI: 2.34 – 3.87] and 5.55 [95%CI: 4.27 – 7.21] for overweight, moderate 
obesity and severe obesity, respectively (Torloni et al., 2009). 
In addition to the principal risk factors, Table 2 provides a detailed list of risk factors from 
previous pregnancies as well as risk factors that may appear during the course of pregnancy 
and may merit investigation. 
www.intechopen.com
 
Gestational Diabetes 
 
44
Personal characteristics: 
Age > 35 years 
Obesity (BMI > 25) 
Arterial hypertension 
Family history of diabetes 
Obstetric history: 
Diabetes in previous pregnancy 
Multiparity 
Recurrent miscarriage 
Prematurity 
Recurrent preeclampsia 
Fetal death, principally in the final weeks of pregnancy  
Neonatal morbidity and mortality: 
- Hypoglycemia  
-  Respiratory distress syndrome 
- Hyperbilirubinemia 
- Hypocalcemia 
- Malformations 
Complications in current pregnancy: 
Excessive weight gain 
Excessive growth of uterine fundal height 
Polyhydramnios 
Fetal macrosomia 
Glycosuria 
Use of hyperglycemic drugs (betamimetics, corticoids) 
Amorim and Katz, 2011 
Table 2. Risk factors for gestational diabetes 
More recently, another systematic review evaluated the available literature, searching for 
further evidence on screening for gestational diabetes (Tieu et al.,2011). The  authors searched 
for articles which evaluated any individual screening tool or screening program, protocol or 
guideline for gestational diabetes compared with the absence of screening; or any individual 
screening tool or screening program, protocol or guideline for gestational diabetes with 
another. Thirty-one trials were considered for inclusion into the review but after application of 
eligibility criteria, only four of these trials were included. After analysis the authors found that 
there was insufficient evidence to determine the effects of screening for gestational diabetes 
and its subsequent management, or the comparative effects of different protocols for 
screening. Although women who were routinely screened by 50 g glucose challenge testing 
were more likely to be diagnosed with gestational diabetes than those screened by their risk 
factors, effects of subsequent management on health outcome are unclear. 
IADPSG recommends investigating “all women or all high-risk women” at their first 
prenatal consultation (IADPSG, Metzger et al., 2010). Universal investigation is justified by 
the increase in the prevalence of undiagnosed type 2 diabetes in young women (Leary et al., 
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2010) and in the risk factors for the occurrence of GD such as, for example, obesity 
(Catalano, 2010). In addition, it ensures that cases of early-onset GD will be identified (Leary 
et al., 2010). Early screening reflects the preference for universal investigation. 
In addition, IADPSG recommends universal investigation at 24-28 weeks of all women not 
previously diagnosed as having clinical or gestational diabetes (IADPSG et al., 2010). 
The argument used by those who support universal screening is based on the randomized 
clinical trial entitled the Australian Carbohydrate Intolerance Study in Pregnant Women 
(ACHOIS) trial group (Crowther et al., 2005), which showed a reduction in healthcare costs 
with universal screening. Nevertheless, criticism to the use of these results for 
recommending IADPSG’s proposal is based on the fact that the ACHOIS study used an oral 
glucose tolerance test of 75 grams, measuring fasting glucose levels and two-hour glucose 
levels alone, whereas the IADPSG recommendations also include measurement of glucose 
levels one hour after overload (Leary et al., 2010). Further studies should be conducted to 
evaluate the costs and benefits associated with this form of management. 
4.2 Diagnosis 
The origin of all this controversy surrounding the diagnosis of GD lies in the form in which 
testing was initially developed. The first authors to develop a diagnostic test for GD were 
John O’Sullivan and Clare Mahan in 1964 (O’Sullivan and Mahan, 1964). The test was 
developed to predict the risk of developing diabetes mellitus years after the pregnancy 
rather than the risk of an adverse perinatal outcome. 
Although it constituted a watershed in the diagnosis of GD, faults were found in the study 
conducted by O’Sullivan and Mahan when analyzed from a methodological point of view, 
particularly with respect to the conclusions drawn and the validation of the test as a 
diagnostic technique, which was clearly demonstrated by Naylor in a study published in 
1989 (Naylor, 1989). One of the questions raised was that gestational diabetes is more 
important as a predictor of a pregnancy with a higher maternal-fetal risk, whereas the end-
point initially evaluated was the presence of carbohydrate intolerance after the end of 
pregnancy. Since the investigators’ objective was to predict the development of diabetes 
mellitus over the long-term, this characteristic was taken into consideration to select the cut-
off points. It was later shown that when pregnant women considered to be diabetic in 
accordance with the values selected were treated with insulin, the rate of macrosomia 
decreased when glucose levels returned to normal (O’Sullivan, 1996 and 1973). This is an 
indirect way of reaching conclusions that is, nonetheless, far from ideal and does not allow 
the diagnostic technique to be adequately validated. According to Naylor, it would have 
been more appropriate to try to record the immediate and long-term neonatal complications 
and test their association using an oral glucose tolerance test. 
In the following years, changes were made to the diagnostic techniques used and glucose 
levels were no longer measured in full blood but rather in venous plasma. Furthermore, 
enzymatic methods began to be used to measure plasma glucose levels instead of the 
Somogyi-Nelson technique. These technical modifications led to the mathematical correction 
of the values initially proposed by O’Sullivan and Mahan with the appearance of different 
sets of values adopted by different organizations involved in the study of GD (National 
Diabetes Data Group [NDDG], 1979; Carpenter and Coustan, 1982). 
Later, an intense debate ensued among investigators regarding the best form of diagnosing 
GD. Many investigators suggested the adoption of more rigid diagnostic criteria, including a 
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reduction in blood glucose levels or the adoption of fewer points on the curve as being 
sufficient for diagnosis. It was even proposed that the presence of hyperglycemia below the 
levels established for diagnosis could be sufficient to lead to adverse maternal and perinatal 
outcomes, or that the hyperglycemia occurring irrespective of an overload should be taken 
into consideration (Aberg et al., 2001; Jensen et al., 2001; Langer et al., 1987; Rudge et al., 
1990; Sermer et al., 1995). 
If on the one hand evidence was accumulating to the effect that milder degrees of 
hyperglycemia, albeit below the levels established for a diagnosis of GD, could lead to 
unfavorable perinatal outcomes, on the other hand some authors questioned the very 
existence of this diagnosis as a valid entity and called attention to the possible negative 
effects of this diagnosis (Buchanan, 1999; Lucas et al., 1993). A diagnosis of GD may result in 
excessive medicalization of pregnancy, which in itself would be negative. Furthermore, this 
diagnosis may result in an increase in the number of interventions performed, including 
even Cesarean sections, in situations in which the need for this type of delivery is 
questionable, due to the mere presence of a diagnosis of diabetes. In addition, it is important 
to remember the psychological burden caused by a label of diabetes. 
In 2005, an Australian group (ACHOIS) published the findings of a randomized clinical trial 
in which mild hyperglycemia was treated in women who did not fulfill the diagnostic 
criteria for GD, but who had measurements of 140 to 199 mg/dl in a 75-gram oral glucose 
tolerance test (OGTT) and were consequently considered to be carbohydrate intolerant 
(Crowther et al., 2005). These investigators found a reduction in composite final outcome 
(perinatal death, shoulder dystocia, fractures and brachial plexus palsy) compared with 
women managed in the usual manner. 
In 2009, a clinical trial was conducted to treat women who were found not to fulfill the 
diagnostic criteria for GD after being submitted to an oral glucose tolerance test with 100 
grams of carbohydrate, but whose glucose levels were not completely normal. Likewise, 
when this group was treated, a reduction was found in macrosomia, shoulder dystocia, 
Cesarean section and hypertensive diseases (Landon et al., 2009). 
Finally, the HAPO (Hyperglycemia and Adverse Pregnancy Outcome) study was conducted 
to evaluate the risks of hyperglycemia during pregnancy for the mother, the fetus and the 
newborn infant (HAPO, 2008). A total of 25,505 women were included and followed up 
prospectively to evaluate a possible association between glucose levels and maternal and 
perinatal outcome. The women were submitted to an OGTT using 75 grams of anhydrous 
glucose. 
The HAPO results were conclusive with respect to the existence of a linear association 
between elevated glucose levels in the pregnant woman and the rates of large-for-
gestational-age infants, preeclampsia and Cesarean sections. Moreover, an association was 
found between maternal hyperglycemia and neonatal hypoglycemia, C-peptide in umbilical 
cord blood, premature delivery, admission to the neonatal intensive care unit (ICU) and 
hyperbilirubinemia. No association was found between maternal hyperglycemia and 
neonatal death; however, the sample size may have been insufficient to evaluate this 
particular outcome. 
One of the most important findings of HAPO was the demonstration of an association that 
is continuous; hence no clear cut-off point can be defined above which adverse events occur 
(Leary et al., 2010). 
The choice of the 75-gram curve to investigate these women has never been validated 
scientifically. The first glucose overload to be described in pregnancy was performed using 
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100 grams of anhydrous glucose (O’Sullivan and Mahan, 1964), a procedure that was also 
recommended by the American Diabetes Association in 2004 (ADA, 2004). Nonetheless, 
since the WHO proposal in 1980 to use a 75-gram overload, as used in non-pregnant 
women, this practice became more and more common and even the HAPO study used the 
75-gram glucose overload. With the power obtained in the HAPO study showing the 
adverse perinatal effects of hyperglycemia associated with the levels obtained following a 
75-gram overload of anhydrous glucose, this test will probably increase in popularity 
compared to the 100-gram overload (Leary et al., 2010). 
Another interesting outcome of the HAPO study was the recommendation that a finding of 
only one abnormal value on the glucose curve should also be considered abnormal and 
diagnostic. This recommendation was made with the aim of increasing the likelihood of 
identifying milder degrees of hyperglycemia that had been associated with poorer maternal 
and perinatal prognosis in previous studies. 
The cut-off points recommended by IADPSG are arbitrarily defined based on an odds ratio 
of 1.75 relative to the mean glucose levels at each time-point, i.e. those measurements that 
result in a 75% greater likelihood of adverse perinatal outcomes. The selection had to be 
made in this way, since, as previously mentioned, the association between glucose levels 
and adverse outcome is continuous. These values, however, are subject to criticism and the 
occurrence of adverse outcomes with glucose levels below the proposed values is to be 
expected. Nevertheless, use of a lower cut-off point would certainly result in a greater 
percentage of diagnosed cases and the impact of this excess number of diagnoses on 
perinatal outcomes has yet to be established (Leary et al., 2010). 
The absence of any IADPSG recommendations regarding a category referred to as 
“carbohydrate intolerance” is noteworthy. According to current criteria, either a woman has 
normal glucose levels or she has gestational diabetes. However, cases need to be taken into 
consideration in which women have glucose levels outside the limits considered normal yet 
without reaching levels that would be considered diagnostic. The adoption of the term 
“carbohydrate intolerance” is suggested for such cases (Leary et al., 2010). 
The findings of the HAPO study appear to indicate that only normal glucose levels would 
eliminate the risk of adverse perinatal outcome; therefore, it could be argued that any 
deviation above normal levels should be considered abnormal (Leary et al., 2010). However, 
the economic and even the psychological impact of so many diagnoses of an “abnormal 
pregnancy” needs to be taken into consideration and may be immense. 
To determine the ideal cut-off point, a cost-benefit analysis has to be performed of different 
cut-off points. In addition to the cost of the diagnostic test itself, the financial burden caused 
by the additional cases diagnosed in terms of follow-up and treatment has to be taken into 
consideration. In addition, it has to be confirmed that treating these diagnosed cases will 
indeed lead to a reduction in the number of adverse outcomes (Leary et al., 2010) and, 
furthermore, that this reduction will cause a positive impact that will compensate for the 
costs of diagnosis and follow-up.  
The change in the diagnostic criteria defined by IADPSG will certainly have significant clinical 
implications for women and for the healthcare system. The number of women diagnosed as 
having gestational diabetes will rise. This increase in the prevalence of GD may cause a 
significant impact on all the additional women who will be diagnosed (Holt et al., 2011). In 
addition to the greater volume of resources required to follow-up and treat these women, the 
effect on patients of the very existence of a diagnosis should be kept in mind. 
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Therefore, this change needs to be supported with convincing data showing beyond doubt 
that its adoption will improve pregnancy outcome. Since the HAPO study was merely 
observational, it is limited to associating adverse perinatal outcomes with higher glucose 
levels; however, it does not prove that normalizing glucose levels will necessarily result in 
any improvement in prognosis (Holt et al., 2011). 
Two studies evaluated the benefits of treating milder degrees of hyperglycemia in 
pregnancy: the ACHOIS study (Crowther, 2005) and the US Multicenter Randomized Trial 
for Treatment of Mild GMD (Landon, 2009). Despite promising results, it should be 
remembered that these studies differed in relation to the glucose levels considered treatable 
and in the number of glucose measurements performed for diagnosis. This hampers 
extrapolation of these results to the findings of the IADPSG study (Holt et al., 2011). 
4.3 Investigation 
The IADPSG proposal for the screening and diagnosis of GD is shown in Table 3: 
 
First prenatal consultation  
Fasting glucose level or hemoglobin A1 (HgA1) or random measurement in women 
• If clinical diabetes => treatment and follow-up for preexisting diabetes.  
• If results are non-diagnostic for clinical diabetes: 
• and fasting glucose level is > 92 and < 126 => diagnosis of GD 
• and fasting glucose level is < 92 => test at 24-28 weeks with OGTT, 75 grams. 
24 - 28 weeks of pregnancy  
OGTT, 75 grams: fasting glucose measurement/1 hour/2 hours 
• Consider clinical diabetes if fasting glucose > 126 
•  Consider GD if ONE or more measurements are above the cut-off points. 
• Consider normal if all the values are below the cut-off points. 
 
For a diagnosis of GD  (OGTT, 75g) 
Fasting glucose  > 92 mg/dl 
Glucose level at 1 hour after 
overload  
>180 mg/dl 
Glucose level at 2 hours after 
overload 
>153 mg/dl 
For a diagnosis of clinical diabetes during pregnancy (any one of these tests)  
Fasting glucose  > 126 mg/dl 
Hemoglobin A1  > 6.5% 
Random plasma glucose 
measurement 
> 200 mg/dl 
Table 3. Screening and diagnosis of GD according to the IADPSG 
It is important, however, to call attention to the fact that controversies persist, despite the 
enormous number of studies conducted in this field. Analyzing the guidelines drawn up by 
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the different organizations, it is clear that there is no consensus with respect to the quantity 
of glucose that should be used in the oral glucose tolerance test (OGTT), to the glucose levels 
that should be considered abnormal, or to the number of abnormal measurements on the 
curve that would permit a diagnosis of GD to be made (Holt et al., 2011). 
Table 4 shows the different criteria currently adopted for a diagnosis of gestational diabetes. 
 
Organization 
Glucose 
overload 
Number of 
abnormal 
values 
required 
Fasting 
glucose levels
Glucose 
levels after 1 
hour 
Glucose 
levels after 
2 hours 
IADPSG 75g > 1 
5.1mmol/l 
92mg/dl 
10.0mmol/l
180mg/dl 
8.5mmol/l 
153mg/dl 
WHO 75g > 1 
7.0mmol/l 
126mg/dl 
 
7.8mmol/l 
140mg/dl 
ADA 100g > 2 
5.3mmol/l 
95mg/dl 
10.0mmol/l
180mg/dl 
8.6mmol/l 
155mg/dl 
ADIPS 75g > 1 
5.5mmol/l 
100mg/dl 
 
8.0mmol/l 
144mg/dl 
CDA 75g > 2 
5.3mmol/l 
95mg/dl 
10.6mmol/l
190mg/dl 
8.9mmol/l 
160mg/dl 
EASD 75g > 1 
6.0mmol/l 
108mg/dl 
 
9.0mmol/l 
162mg/dl 
NZSSD 75g > 1 
5.5mmol/l 
100mg/dl 
 
9.0mmol/l 
162mg/dl 
ADA: American Diabetes Association (until autumn 2010); ADIPS: Australasian Diabetes 
in Pregnancy Society; CDA: Canadian Diabetes Association; EASD: European Association 
for the Study of Diabetes; IADPSG: International Association of Diabetes and Pregnancy 
Study Groups; NZSSD: New Zealand Society for the Study of Diabetes; WHO: World 
Health Organization. *The ADA adopted the IAPDSG criteria in the autumn of 2010. 
Holt et al, 2011 
Table 4. Comparison of diagnostic criteria for gestational diabetes 
Until randomized clinical trials are conducted to compare the different strategies for 
screening and diagnosis and to define possible differences in maternal and perinatal 
outcome, the ideal test and the ideal criteria remain to be defined. The characteristics of each 
population should be evaluated, principally with respect to the frequency of gestational 
diabetes and macrosomia. In populations with a high risk for diabetes, we suggest that the 
IADPSG criteria be used; however, in low-risk populations in which there is no significant 
association between macrosomia and gestational diabetes, these criteria may not be 
applicable (Leary et al., 2010). 
5. Treatment of gestational diabetes 
5.1 Rationale for treatment 
Normally, the proposal of any strategy for screening and diagnosis of gestational diabetes is 
aimed at establishing a therapeutic plan for diagnosed cases, since available evidence 
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suggests that adequate treatment successfully reduces maternal and fetal morbidity, 
particularly macrosomia (Crowther et al., 2005; Langer et al., 2005; Landon et al., 2009). 
Various therapeutic options are available such as diet, physical exercise, blood glucose 
monitoring and insulin therapy in cases in which diet alone fails to maintain adequate 
glucose levels (Pridjian and Benjamin, 2010). This chapter does not explore the details of 
each individual treatment, but simply reviews the available evidence regarding the need for 
treatment and its effectiveness. 
A systematic review in the Cochrane Library specifically deals with the various alternative 
therapeutic options for gestational diabetes (Alwan et al., 2011). Eight randomized clinical 
trials involving a total of 1,418 women were included in which any form of treatment was 
compared with routine prenatal care or different treatments were compared with each 
other. Except for one large Australian study published in 2005 that included 1,000 women 
(ACHOIS trial) (Crowther et al., 2005), the sample sizes were small in all the other studies. 
When the treatment of mild hyperglycemia was compared with routine prenatal care, a 
significant reduction was found in the risk of preeclampsia and an increase in the risk of 
induced labor in the group that received treatment. There were no differences in Cesarean 
section rates, rates of hospital admission, instrumental delivery or postpartum hemorrhage 
or in the duration of hospital stay. With respect to perinatal outcome, the treatment of 
diabetes resulted in a significant reduction in composite perinatal morbidity (death, 
shoulder dystocia, bone fracture and nerve palsy), as well as in the frequency of macrosomia 
(birthweight > 4000 grams) and shoulder dystocia. Although in the ACHOIS study the rate 
of admittance to a neonatal intensive care unit was higher for the infants of mothers who 
received treatment for hyperglycemia, in the meta-analysis this difference was not found to 
be statistically significant. There were no significant differences between the two groups 
with respect to gestational age at delivery, incidence of bone fracture in newborn infants, 
incidence of nerve palsy in the newborn, perinatal death, neonatal hypoglycemia, incidence 
of respiratory distress syndrome in the newborn infant or in the need for mechanical 
ventilation. The conclusion reached by these reviewers was that specific treatment for mild 
gestational diabetes, including diet and insulin, reduces the risk of maternal and perinatal 
morbidity; however, the risk of labor induction increases. Further studies need to be 
conducted to evaluate the effect of the different therapeutic modalities, including oral 
hypoglycemic drugs and insulin, on infant short and long-term outcomes. 
Specific analysis of the findings of the ACHOIS trial reveals a frequency of severe neonatal 
morbidity of 1% in the treated group compared to 4% in the group that received routine 
care. The incidence of neonatal admission to hospital was 71% versus 61%, respectively, 
whereas rates of labor induction were 39% in the treatment group versus 29% in the group 
receiving routine care. The rate of Cesarean sections was similar in both groups, 31% versus 
32%. In addition, lower rates of depression and better quality of life scores were found in the 
treated women in the ACHOIS trial at three months postpartum (Crowther et al., 2005). 
Another large randomized clinical trial conducted in the United States was published in 
2009 and has yet to be included in the Cochrane systematic review (Landon et al., 2009). The 
study included 958 women. There was no statistically significant difference in composite 
outcome (32.4% in the treated group and 37% in the control group) and no perinatal deaths 
occurred in either group. Nevertheless, birthweight was significantly lower in the treated 
group (3302 grams versus 3408 grams), as was the frequency of large-for-gestational-age 
infants (7.1% versus 14.5%), fetal macrosomia (5.9% versus 4.0%), shoulder dystocia (1.5% 
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versus 4.0%) and Cesarean sections (26.9% versus 33.8%). The rates of preeclampsia and 
gestational hypertension were also lower in the treated group (8.6% versus 13.6%). 
A more recent systematic review on the treatment of gestational diabetes included 18 
studies, five of which compared the specific treatment of diabetes with routine treatment 
(including the 2009 US trial). Modest effects of treatment were found, including a reduction 
in the risk of fetal macrosomia and shoulder dystocia and a trend, albeit non-significant, 
towards a reduction in the rate of Cesarean sections. Different levels and intensity of 
treatment were compared in 13 trials, with findings showing a significant reduction in risk 
only with respect to shoulder dystocia in the group receiving intensive treatment (Horvath 
et al., 2010). 
Based on the results of these more recent studies, we believe that it is important to diagnose 
and treat gestational diabetes in order to reduce maternal and neonatal morbidity. Data 
from the Hyperglycemia and Adverse Pregnancy Outcomes study (HAPO, 2008) reinforce 
this recommendation, since findings showed a significant association between increasing 
glucose levels and maternal complications such as preeclampsia, and neonatal 
complications such as macrosomia and metabolic alterations (Leary et al., 2010), leading, as 
previously discussed, to changes in the diagnostic criteria for gestational diabetes, as 
defined by the International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) (Metzger et al., 2010). Nonetheless, some criticism remains with respect to the 
comparability of the HAPO study with the more recent clinical trials, since different 
screening strategies were used (Horvath et al., 2010). 
5.2 Treatment strategies 
5.2.1 Diet 
The universal recommendation has been that all women with a confirmed diagnosis of 
gestational diabetes should receive dietary counseling and initiate an appropriate diet with 
the aim of normalizing glucose levels, preventing ketosis, ensuring adequate weight gain 
and contributing towards fetal well-being. The number of calories will depend on the 
woman’s current weight, with an allowance of 30 kcal/kg of current weight for women with 
a normal body mass index (BMI), 24 kcal/kg for overweight women and 12-15 kcal/kg for 
obese women. Carbohydrates (preferably complex carbohydrates) should correspond to 33-
40% of the total number of calories, with protein corresponding to 20% and fat to 40%, 
provided in the form of three main meals and three snacks. Moderate use of sweeteners 
such as aspartame is permitted. Following these dietary guidelines, glucose levels will 
normalize in around 75-80% of women with gestational diabetes (ADA, 2004). 
Nevertheless, the most adequate strategy for the control of gestational diabetes still remains 
to be defined, since diet alone may fail to prevent macrosomia. A systematic review 
available in the Cochrane Library included four studies with 612 women with gestational 
diabetes and failed to find any differences in the rates of macrosomia (OR = 0.78; 95%CI: 
0.45 – 1.35) or Cesarean section (Walkinshaw, 2011). However, the clinical trials included in 
this review were all small and old, with variations in quality and very wide confidence 
intervals that did not permit evaluation of the validity of dietetic therapy. The reviewers 
concluded that there is insufficient evidence to evaluate the use of primary dietetic therapy 
for women with impaired glucose metabolism in pregnancy. They recommended that larger 
studies should be conducted to evaluate the effects of diet on maternal outcome 
(particularly Cesarean sections) and perinatal outcome. 
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Compliance with treatment and weight gain constitute factors capable of modifying 
response to dietetic treatment. One large retrospective study including more than 30,000 
women with gestational diabetes showed that in the women in whom weight gain was 
adequate maternal and perinatal outcomes were favorable, whereas those in whom weight 
gain was excessive had a higher risk of large-for-gestational-age infants, premature delivery 
and Cesarean sections (Cheng et al., 2008). 
5.2.2 Physical exercise 
Physical exercise has been proposed as part of the treatment for gestational diabetes based 
on the fact that, in adults, an improvement in physical fitness increases insulin sensitivity, 
improves glucose control and reduces the need for insulin (Colberg et al., 2010). 
A systematic review available in the Cochrane Library evaluated the effects of exercise 
programs alone or in association with other therapies on maternal and perinatal morbidity 
in pregnant women with diabetes. The review included four small, randomized clinical 
trials involving 114 women with gestational diabetes recruited during the third trimester of 
pregnancy. The intervention (exercise) was performed over six weeks. There were no 
statistically significant differences between the group that performed exercise and the 
controls for any one of the endpoints evaluated. The authors’ conclusion was that the 
evidence was insufficient to either recommend or contraindicate exercise for pregnant 
women with diabetes and that larger randomized clinical trials should be conducted to 
further evaluate this form of intervention (Ceysens et al., 2011). 
Despite the consistent lack of evidence on the effects of exercise on maternal and perinatal 
prognosis in women with gestational diabetes, the American Association of Diabetes (ADA) 
suggests a program of moderate exercise as part of the therapeutic management of women 
with gestational diabetes as long as there are no medical or obstetrical contraindications to 
this level of physical activity (ADA, 2004). 
5.2.3 Monitoring glucose levels 
Monitoring glucose levels may also alter the progression of the condition in women with 
gestational diabetes. One study showed that daily monitoring of pregnant women treated 
with diet allows identification of those who could benefit from treatment with an anti-
hyperglycemic agent, which may lead to a reduction in the rates of macrosomia (Hawkins et 
al., 2009; Hawkins, 2010). Nevertheless, the ideal frequency of self-monitoring in women 
with diet controlled gestational diabetes remains to be established and there is insufficient 
evidence regarding the ideal glucose levels and the duration of control that would allow 
longer intervals between capillary glucose measurements (Metzger, 2007). 
With respect to the timing and frequency of capillary glucose monitoring, although there are 
still some controversies between investigators, most of them currently recommend 
measuring fasting levels immediately after waking and one hour after meals. The proposal 
for self-monitoring made by some specialists is to test capillary glucose levels four times a 
day in cases of diet controlled gestational diabetes (fasting and one hour after each meal) 
and six times a day in gestational diabetes requiring the use of insulin (fasting, one hour 
prior to and one hour after each meal) (Jovanovic, 2008). 
A clinical trial comparing monitoring with schedules that involve either the measurement of 
pre-prandial glucose levels or fasting glucose and postprandial levels (one hour after meals) 
in patients with gestational diabetes using insulin therapy showed a better control of 
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glucose levels, a lower rate of large-for-gestational-age infants and a lower rate of Cesarean 
sections with the latter protocol (deVeciana et al., 1995). Comparing monitoring one hour 
postprandial with two hours postprandial, a prospective, observational study found less 
need for insulin therapy and a trend towards lower rates of fetal macrosomia and Cesarean 
sections with one-hour postprandial glucose measurements (Weisz et al., 2005). There is 
insufficient evidence to determine the role of continuous glucose monitoring in patients 
with gestational diabetes, although this may be useful in women who require insulin and 
who have difficulty in achieving adequate control of glucose levels (Hawkins, 2010). 
5.2.4 Pharmacological treatment 
5.2.4.1 Insulin therapy 
With respect to insulin therapy, there is no consensus on the glucose levels that would 
indicate that insulin should be initiated after the implementation of dietetic therapy. The 
American College of Obstetricians and Gynecologists (ACOG) suggests that insulin should 
be administered to reduce the risk of macrosomia with fasting glucose levels ≥ 95 mg% OR 
one-hour postprandial glucose levels > 130-140 mg% OR two-hour postprandial glucose 
levels ≥ 120 mg% (ACOG, 2001). There are no randomized clinical trials available in which 
different glucose levels were compared with the objective of determining the cut-off point 
for the implementation of insulin therapy. Three randomized clinical trials suggest initiating 
insulin therapy irrespective of glucose levels if ultrasonographic measurement of fetal 
abdominal circumference exceeds the 75th percentile (Bonomo et al., 2004; Kjos et al., 2001; 
Rossi et al., 2000). The doses and types of insulin will not be discussed in this chapter. 
5.2.4.2 Antihyperglycemic drugs 
Oral hypoglycemic drugs are classically contraindicated in pregnancy. First generation 
drugs such as chlorpropamide and tolbutamide cross the placental barrier and may 
potentially cause prolonged and profound states of hypoglycemia, leading to fetal 
malformation. Nevertheless, the newer hypoglycemic drugs such as glibenclamide do not 
enter fetal circulation (Langer, 2007). 
Furthermore, considering that in patients with gestational diabetes, the need for treatment 
initiates after embryogenesis (Langer, 2007), the newer oral hypoglycemic drugs were seen 
as a practical therapeutic option for this group of patients. Patient satisfaction with this 
route of administration may result in better compliance with treatment. Interest in 
evaluating these drugs as an option for the control of gestational diabetes has been intense 
and various randomized clinical trials using these agents have been published over the past 
ten years (Langer et al., 2000; Moore et al., 2010; Rowan et al., 2008). 
In 2008, a systematic review was published that included a meta-analysis of all the clinical 
trials in which the use of insulin was compared with glibenclamide in women with gestational 
diabetes. Nine clinical trials were included involving 1,382 women with gestational diabetes. 
The use of glibenclamide was not found to be associated with any increased risk of 
macrosomia nor with differences in relation to fetal weight or the frequency of large-for-
gestational-age infants, admission to the neonatal ICU or an increased risk of neonatal 
hypoglycemia. These findings suggest that there is no increased perinatal risk with the use of 
this drug; however, the effectiveness and safety of its use still need to be confirmed, since the 
majority of the studies included were not randomized (Moretti et al., 2008). 
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Another systematic review published by the Johns Hopkins University Evidence-Based 
Practice Center for the Agency for Healthcare Research and Quality evaluated oral 
hypoglycemic drugs in women with gestational diabetes. Nine studies were selected, four of 
which consisted of randomized clinical trials involving 1,229 participants, while five were 
observational studies involving 831 participants. Two clinical trials compared insulin with 
glibenclamide, while one compared glibenclamide with acarbose and another compared 
insulin with metformin. No statistically significant differences were found with respect to 
glycemic control, the weight of the newborn infant or in the rate of Cesarean sections when 
insulin was compared with glibenclamide. There was a greater proportion of newborn infants 
with hypoglycemia in the group that used insulin (8.1% versus 3.3%; p = 0.008). No statistically 
significant difference was found in the rate of congenital malformations when the pregnancies 
treated with insulin were compared with those treated with oral hypoglycemic drugs. The 
authors concluded that there are no substantial differences in maternal and neonatal outcomes 
between women with gestational diabetes using insulin and those using oral hypoglycemic 
drugs (glibenclamide and metformin) (Nicholson et al., 2009). 
The most recent systematic review on oral hypoglycemic drugs for the treatment of 
gestational diabetes showed no difference either in glycemic control or in the outcome of 
pregnancy when insulin was compared with hypoglycemic drugs in six randomized clinical 
trials involving a total of 1,388 pregnant women. There was no increased risk of neonatal 
hypoglycemia, macrosomia or Cesarean section, and maternal glucose levels were similar 
(Dhulkotia et al., 2010). 
Results with the use of glibenclamide for the treatment of gestational diabetes are 
encouraging and although the ADA and ACOG consensuses recommend not prescribing 
glibenclamide for women with gestational diabetes (ACOG, 2001; ADA 2004), it would 
appear that there is already sufficient and consistent evidence confirming its safety and 
effectiveness in this condition. Another issue to be evaluated with respect to glibenclamide 
is its cost, which is significantly lower compared to treatment with insulin (Melamed and 
Yogev, 2009). Nevertheless, the United States Food and Drug Administration (FDA) has not 
approved these drugs for this purpose. 
5.2.5 Obstetric treatment 
5.2.5.1 Evaluation of fetal vitality 
Randomized clinical trials have yet to be conducted to evaluate the need for antenatal 
testing or the type of antenatal tests for the assessment of fetal well-being. Nonetheless, the 
fetuses of women with gestational diabetes, depending on glycemic control, may be at an 
increased risk of macrosomia (Durnwald et al., 2011) and intrauterine death (Yogev and 
Visser, 2009), and some observational studies have reported a reduction in the risk of fetal 
loss with various protocols for evaluating vitality (Graves, 2007; Kjos et al., 2005). 
In 2001, the ACOG concluded that there is insufficient evidence to determine the ideal scheme 
for monitoring antepartum fetal vitality in women with gestational diabetes controlled by diet 
and in whom there are no additional perinatal risks (ACOG, 2001). The evaluation of fetal 
vitality in cases of gestational diabetes may include fetal biophysical profile and antepartum 
cardiotocography. Doppler blood flow measurement is not useful for evaluating fetal vitality 
in this context (Graves, 2007). The frequency with which these tests should be performed 
depends on the classification of diabetes and is not routinely recommended in cases controlled 
with diet (ACOG, 2001; Conway, 2007). In women who require insulin or antihyperglycemic 
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drugs, it has been suggested that monitoring should be performed twice weekly beginning at 
32 weeks (ACOG, 2001). The method of evaluating vitality and the periodicity of this 
evaluation, however, remains to be determined and varies in accordance with the protocol 
implemented in the service and the clinical situation (Conway, 2007). 
5.2.5.2 Screening for fetal macrosomia 
Macrosomia may be investigated by performing a single ultrasonography scan in the 36th 
week of pregnancy or by serial scans from 28 weeks onwards (Ben-Haroush et al., 2007). 
Nevertheless, the poor accuracy of ultrasonography for the prediction of fetal weight limits its 
use for this purpose (Wong et al., 2001). Based on specialist opinion, it has been suggested that 
fetal growth monitoring and the investigation of macrosomia is unnecessary in cases of 
gestational diabetes controlled by diet, principally because false-positive results may lead to 
unnecessary Cesarean sections (Melamed et al., 2010). Fetal weight estimated by 
ultrasonography would have to be ≥ 4,800 grams to have at least a 50% chance of predicting an 
infant being born with a birthweight of 4,500 kg or more (McLaren et al., 1995). 
5.2.5.3 Anticipating delivery 
Treatment of gestational diabetes may include anticipating delivery through induction or by 
elective Cesarean section. In a systematic review of the Cochrane Library, the policy of 
electively interrupting pregnancy by inducing labor in full-term diabetic women was 
evaluated (Boulvain et al., 2011). Only one study involving 200 women was included. 
Results showed that induction at 38 weeks reduced the frequency of newborn infants 
weighing > 4000 grams and above the 90th percentile, which is not surprising, since 
gestational age at delivery was lower in the induction group. This intervention, however, 
failed to reduce the risk of Cesarean section or of neonatal morbidities. Therefore, the 
authors concluded that further studies involving larger sample sizes are required in order to 
confirm the advantages of this intervention. Up to the present moment, there is insufficient 
evidence to enable this practice to be recommended. 
More recently, a systematic review including five studies (the same clinical trial included in 
the Cochrane review plus four observational studies) compared active management at term 
(induction or Cesarean section) with expectant management. The results of the randomized 
clinical trial were similar to the findings of the previous systematic review. When the four 
observational studies were analyzed, however, a potential reduction was found in the rate of 
macrosomia, of shoulder dystocia in induced deliveries and in Cesarean sections indicated 
because of fetal macrosomia. The authors concluded that active management appears to 
reduce the rates of macrosomia and its complications; however, further clinical trials are 
clearly necessary to strengthen the evidence and support clinical practice (Witkop et al., 2009). 
The ACOG suggests performing elective Cesarean sections as a means of reducing the risk of 
shoulder dystocia in cases of gestational diabetes when estimated fetal weight is ≥ 4,500 grams 
(ACOG, 2001). In diabetic pregnant women in whom estimated fetal weight is below 4,000 
grams, Cesarean section is unjustified on the basis of fetal weight alone (Hawkins and Casey, 
2007). On the other hand, the management of cases in which estimated fetal weight is between 
4,000 and 4,500 grams remains controversial. In addition to estimated fetal weight, the size of 
the mother’s pelvis and the progression of labor should also be taken into consideration when 
deciding on the type of delivery (Hawkins and Casey, 2007). It should also be noted that the 
limited accuracy of ultrasonography for adequately estimating fetal weight leads to 
unnecessary Cesarean sections because of the suspicion of macrosomia (Chauhan et al., 2005). 
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In the absence of macrosomia, specialists suggest that patients with gestational diabetes 
controlled by diet may be able to reach 40/41 weeks and recommend induction at this 
gestational age. In patients in use of insulin or oral antihyperglycemic drugs, labor should 
be induced at 39 weeks. In diabetic patients in use of insulin or those in whom glycemic 
control is poor, labor should be induced at 38 weeks and even prior to this gestational age if 
there are associated conditions such as severe preeclampsia, for example, or if fetal well-
being is compromised. There is no need for amniocentesis to evaluate fetal lung maturity in 
patients after 38 weeks of pregnancy when gestational age is well documented (Conway et 
al., 2007; Nicholson et al., 2008). 
6. Conclusions 
The most recent evidence suggests that screening for gestational diabetes is beneficial; 
however, the best screening strategy remains to be defined. Clinical trials also need to be 
conducted to compare various diagnostic tests and glucose levels; however, until these studies 
are performed, clinicians and societies have to define their own protocols for screening and 
diagnosis taking the characteristics of the population to be screened into consideration. In 
populations with a high risk for diabetes and consequently for macrosomia, a universal 
screening policy leads to a significant reduction in perinatal morbidity.  
With respect to treatment, although the Cochrane systematic review found only modest 
benefits with treatment, more recent randomized clinical trials suggest an improvement in 
perinatal outcome. Based on specialist opinion, initial dietetic therapy is recommended, 
with pharmacological treatment indicated when diet alone fails to control glucose levels. 
Despite recent evidence that treatment with antihyperglycemic drugs may represent a safe, 
reliable alternative for the pharmacological treatment of diabetes in pregnancy, the ADA 
and other guidelines continue recommending insulin therapy as standard treatment. There 
is insufficient evidence either to indicate or contraindicate exercise in women with 
gestational diabetes. 
The types of tests and the ideal frequency at which fetal well-being should be monitored are 
factors that are yet to be determined; however, they are unnecessary in cases in which 
glucose levels are controlled by diet. In addition, there is insufficient evidence to 
recommend ultrasonography for the prediction of macrosomia and scans should not be 
performed routinely for this purpose in pregnant women on dietetic therapy in whom 
glucose levels are under control. 
With respect to delivery, elective Cesarean sections are recommended by ACOG in the case 
of fetuses over 4,500 grams. In cases of gestational diabetes controlled by diet, it is possible 
to wait for spontaneous labor to occur up to a limit of 40/41 weeks. In patients in use of 
insulin or oral hypoglycemic drugs, labor should be induced at 39 weeks. In cases in which 
glucose control is poor, delivery should be anticipated at 38 weeks or earlier if fetal well-
being is compromised or there are other associated morbid conditions. 
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